EUCTR2011-000425-72-IT
Active, not recruiting
Not Applicable
Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection - Ozurdex in post-occlusive macular edema
IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS0 sitesMay 13, 2011
Conditionsmacular edema seconday to central or branch retinal vein occlusionMedDRA version: 13.1Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disorders
DrugsOZURDEX
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- macular edema seconday to central or branch retinal vein occlusion
- Sponsor
- IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Macular edema with a duration \<12 months 2\. Central retinal vein occlusion 3\. Branch retinal vein occlusion 4\. Best correct visual acuity (BCVA) in the study eye \= 20/400 4\. Central retinal thickness \= 250 micron by OCT
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\. Any other ocular condition that might permanently impair the visual acuity in study eye including amblyopia, anterior ischemic optic neuropathy 2\. Previous surgery in the study eye, such also cataract extraction, within 3 months before the study 3\. any intravitreal injection in the study eye including Ozurdex injection or anti\-VEGF drugs within 4 months before the enrollment 4\. Pregnancy or breast\-feeding 5\. Advanced glaucoma 6\. Active ocular or periocular infection 7\.any ocular allergies versus active drugs or excipients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Treatment of macular edema secondary to central vein occlusiocentral vein occlusion.Other retinal vascular occlusionsIRCT201011295270N1Banco de Olhos de Sorocaba15
Active, not recruiting
Phase 1
Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®). - Lucentis in CRVOThis case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion.MedDRA version: 12.1Level: LLTClassification code 10007972Term: Central retinal vein occlusionMedDRA version: 12.1Level: LLTClassification code 10054467Term: Macular edemaEUCTR2009-017782-30-ATMedizinische Universität Graz, Universitäts-Augenklinik
Completed
Not Applicable
Treatment of macular edema secondary to branch retinal vein occlusion with sub-tenon triamcinolone acetonide injectioMacular edema following BRVOJPRN-UMIN000031215Aichi Medicak University Department of Ophthalmology60
Recruiting
Phase 4
Therapy of recalcitrant macular edema in aphakic and/or eyes with with severe iris-lens diaphragm disruption with longterm intravitreal steroid implants such as Iluvien® or Ozurdex®.recalcitrant macular edemaH35.8Other specified retinal disordersDRKS00020282Augenklinik des Klnikums der Ludwig-Maximilians-Universität München40
Active, not recruiting
Phase 1
Treatment of Cystoid Macular Edema following cataract surgery. A randomized, double-masked, placebo-controlled, clinical trial. - Treatment of post-cataract CMEEUCTR2009-017031-18-NLRotterdam Eye Hospital25